A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). (Q114969615)
Jump to navigation
Jump to search
scientific article published in 2022
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). |
scientific article published in 2022 |
Statements
A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). (English)
Gwo Fuang Ho
Soo-Chin Lee
Joanna Lim
Anita Zarina Bustam
Siew Eng Lim
Marniza Saad
Samuel Guan Wei Ow
Natalie Ngoi
Nur Fadhlina Abdul Satar
Rozita Abdul Malik
Adlinda Alip
Kian Boon Law
Yok Yong Toh
Jia Wern Pan
Soo Hwang Teo
1 June 2022
1026-1026
16_suppl